SCHEMBL833522

SCHEMBL833522

O=C(NC#Cc1ccccc1)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CYP3A4 P08684 1/20 0.52
PLOD2 O00469 1/20 0.51
PTGS2 P35354 1/20 0.51
KCNK3 O14649 1/20 0.51
GAA P10253 3/20 0.50
ALDH1A1 P00352 1/20 0.50
APP P05067 1/20 0.50
HCAR3 P49019 1/20 0.50
HCAR2 Q8TDS4 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
THRB P10828 1/20 0.50
LMNA P02545 1/20 0.50
HIF1A Q16665 1/20 0.50
CYP2C9 P11712 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL157858 0.84 HDAC3 (0.48) HDAC1HDAC6PTGS2GAAALDH1A1
SCHEMBL3247808 0.77 HDAC1 (0.65) HDAC1HDAC6PLOD2PTGS2KCNK3
SCHEMBL3248996 0.76 HDAC1 (0.62) HDAC1HDAC6PLOD2PTGS2GAA
SCHEMBL7467601 0.76 HDAC1 (0.62) HDAC1HDAC6PLOD2PTGS2KCNK3
SCHEMBL2718279 0.76 HDAC1 (0.62) HDAC1HDAC6PLOD2PTGS2KCNK3
SCHEMBL5361922 0.75 GAA (0.77) HDAC1HDAC6CYP3A4PLOD2PTGS2
SCHEMBL29011921 0.75 GAA (0.71) HDAC1HDAC6CYP3A4PLOD2PTGS2
SCHEMBL28358478 0.74 ALDH1A1 (0.54) PLOD2GAAALDH1A1APPHCAR3
SCHEMBL8162429 0.73 HDAC1 (0.69) HDAC1HDAC6PLOD2PTGS2KCNK3
SCHEMBL28876818 0.73 MAPT (0.50) HDAC1HDAC6CYP3A4ALDH1A1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383825-B2 Kinase inhibitors ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20120207810-A1 Kinase Inhibitors SPADA LON T (US) 2012-08-16 US disclosed
US-8143410-B2 Kinase inhibitors ALLERGAN, INC. (US) 2012-03-27 US disclosed
US-20110263611-A1 Kinase Inhibitors ALLERGAN, INC. 2011-10-27 US disclosed
US-7915443-B2 Sulfoximines as kinase inhibitors ALLERGAN, INC. (US) 2011-03-29 US disclosed
US-20090196906-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-06 US disclosed
US-20090099181-A1 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263611-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 HDAC1 962/4885HDAC6 1268/4885CYP3A4 4156/4885
US-20120207810-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 HDAC1 962/4885HDAC6 1268/4885CYP3A4 4156/4885
US-20090196906-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 HDAC1 962/4885HDAC6 1268/4885CYP3A4 4156/4885
US-20090099181-A1 SULFOXIMINES AS KINASE INHIBITORS SRC, PTK2B, TYRO3 HDAC1 1719/4885HDAC6 2049/4885CYP3A4 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.